Finance

Lists
BBOT:NASDAQ
BridgeBio Oncology Therapeutics Inc
3,40 USD
-0,58%
(-0,020) 1D
9-окт., 12:09:23 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for BBOT...
Open
3,43 USD
High
3,50 USD
Low
3,37 USD
Mkt. cap
272,59 млн
Avg. vol.
672,97 миң
Volume
222,23 миң
52-wk high
14,87 USD
52-wk low
3,27 USD
EPS
-3,04 USD
Shares outstanding
80,17 млн
No. of employees
88
Open
3,43 USD
High
3,50 USD
Low
3,37 USD
Mkt. cap
272,59 млн
Avg. vol.
672,97 миң
Volume
222,23 миң
52-wk high
14,87 USD
52-wk low
3,27 USD
EPS
-3,04 USD
Shares outstanding
80,17 млн
No. of employees
88
News stories
From web sources and news partners
About BridgeBio Oncology Therapeutics Inc
CEO-
Employees88
Founded2016
HeadquartersЮг Сан Франциско, Калифорния, Америка Кошмо Штаттары
Sector-
Websitebbotx.com
Analyst ratings
Based on 9 analysts giving stock ratings to BBOT in the past 3 months
Strong buy
Buy
9
Hold
0
Sell
0
12-month forecast
Based on 9 Wall Street analysts offering 12 month price targets for BBOT in the last 3 months.
Highest
Current 3,40 USD
25,00 USD (+635,29%)
Average
21,00 USD (+517,65%)
Lowest
15,00 USD (+341,18%)
Analyst
Recommendation
Action
Price target
Projected
Date
Andrew Berens
Leerink Partners
Buy
Reiterated
25,00 USD
+635,3%
09/18/2026
Priyanka Grover
J.P. Morgan
Buy
Reiterated
-
-
09/15/2026
Unknown Analyst
Wedbush
Buy
Maintained
25,00 USD
+635,3%
09/09/2026
Biren Amin
Piper Sandler
Buy
Maintained
21,00 USD
+517,6%
09/09/2026
Sean McCutcheon
Raymond James
Buy
Maintained
22,00 USD
+547,1%
09/09/2026
Laura Prendergast
Stifel Nicolaus
Buy
Maintained
15,00 USD
+341,2%
09/09/2026
John Newman
Canaccord Genuity
Buy
Maintained
20,00 USD
+488,2%
09/09/2026
Sean Laaman
Morgan Stanley
Buy
Reiterated
18,00 USD
+429,4%
08/17/2026
Unknown Analyst
J.P. Morgan
Buy
Reiterated
25,00 USD
+635,3%
08/14/2026
Mazahir Alimohamed
Oppenheimer
Buy
Reiterated
22,00 USD
+547,1%
08/12/2026
David Nierengarten
Wedbush
Buy
Maintained
25,00 USD
+635,3%
05/13/2026
Matthew Biegler
Oppenheimer
Buy
Reiterated
22,00 USD
+547,1%
05/13/2026
Robert Burns
H.C. Wainwright
Buy
Reiterated
29,00 USD
+752,9%
05/01/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
35,05 млн
38,07 млн
39,80 млн
49,22 млн
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
14,13 млн
5,33 млн
6,38 млн
10,96 млн
Operating expense
49,18 млн
43,41 млн
46,18 млн
60,19 млн
Total operating expenses
49,18 млн
43,41 млн
46,18 млн
60,19 млн
Operating income
-49,18 млн
-43,41 млн
-46,18 млн
-60,19 млн
Other non operating income
980,00 миң
187,00 миң
129,00 миң
182,00 миң
EBT including unusual items
-44,76 млн
-38,80 млн
-42,11 млн
-56,45 млн
EBT excluding unusual items
-44,76 млн
-38,80 млн
-42,11 млн
-56,45 млн
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-44,76 млн
-38,80 млн
-42,11 млн
-56,45 млн
Net profit margin
-
-
-
-
Earnings per share
-1,03
-0,49
-0,53
-0,71
Interest and investment income
3,44 млн
4,42 млн
3,94 млн
3,55 млн
Interest expense
-
-
-
-
Net interest expenses
3,44 млн
4,42 млн
3,94 млн
3,55 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
-49,11 млн
-43,32 млн
-46,10 млн
-60,11 млн
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google колдонмолору